Skip to main content

SLP

Stock
Health Care
Health Information Services

Performance overview

SLP Price
Price Chart

Forward-looking statistics

Beta
0.44
Risk
45.14%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. It generates maximum revenue from the software segment.

Company info

SectorHealth Care
IndustryHealth Information Services
Employees154
Market cap$923.7M

Fundamentals

Enterprise value$330.3M
Revenue$78.6M
Revenue per employee—
Profit margin9.24%
Debt to equity0.42

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$0.36
Dividend per share$0.24
Revenue per share$3.92
Avg trading volume (30 day)$6M
Avg trading volume (10 day)$7M
Put-call ratio—

Macro factor sensitivity

Growth-1.8
Credit+7.8
Liquidity+1.2
Inflation-5.4
Commodities-0.3
Interest Rates-1.5

Valuation

Dividend yield1.42%
PEG Ratio16.83
Price to sales4.44
P/E Ratio16.83
Enterprise Value to Revenue4.21
Price to book1.84

Upcoming events

Next earnings dayJanuary 8, 2025
Next dividend day—
Ex. dividend dayJuly 29, 2024

News

Simulations Plus Sees Weaker Demand Persist, Outlook Softens

Simulations Plus Inc. SLP shares declined on Tuesday following the release of its third-quarter 2025 earnings report.

Benzinga (July 15, 2025)
SLP's Q3 Earnings Top, Sales Up Y/Y, Stock Gains Despite Lowered View

Simulation Plus' fiscal Q3 2025 earnings surge 67% on Pro-ficiency gains, but a cut in 2025 outlook shows hurdles in biosimulation and services.

Zacks Investment Research (July 15, 2025)
Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Tuesday.

Benzinga (July 15, 2025)
Simulations Plus (SLP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research (July 7, 2025)
Simulations Plus Slashes Guidance Amid Biotech Spending Cuts, Analyst Expresses Doubt

Simulations Plus Inc SLP stock tanked after the company lowered its fiscal 2025 sales outlook.

Benzinga (June 12, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free